I would say all of your posts are redundant. Typically I read posts without noticing who writes them, but yours stand out to me because they are always in the same vein.
This is not a penny stock. I own 1850 shares and I'm betting that's more than possibly everyone here. Your posts aren't influencing me and even if it did, my 1850 shares is a mere tiny bucket and would have zero impact if I were to sell today. Probably not even move the stock price a penny.
So, in essence, your posts here are saying the same thing with little impact. And in fact, since I've been noticing your posts putting down the company, I would say the share price has held up fairly well.
So, I guess my last question is the one I absolutely hate on the penny stock boards, but I will ask it anyway. If you don't own the stock, what is your purpose for posting here?
This is not a penny stock. I own 1850 shares and I'm betting that's more than possibly everyone here. Your posts aren't influencing me and even if it did, my 1850 shares is a mere tiny bucket and would have zero impact if I were to sell today. Probably not even move the stock price a penny.
So, in essence, your posts here are saying the same thing with little impact. And in fact, since I've been noticing your posts putting down the company, I would say the share price has held up fairly well.
So, I guess my last question is the one I absolutely hate on the penny stock boards, but I will ask it anyway. If you don't own the stock, what is your purpose for posting here?
"Good night, Westley. Good work. Sleep well. I'll most likely kill you in the morning."
Recent GILD News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/28/2026 08:12:50 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 04/28/2026 01:13:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 12:56:25 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 04/28/2026 12:53:40 PM
- Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel • Business Wire • 04/28/2026 12:45:00 PM
- Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026 • Business Wire • 04/22/2026 08:05:00 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 04/17/2026 01:00:24 PM
- Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer • Business Wire • 04/17/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/16/2026 10:41:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/16/2026 10:40:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/15/2026 08:12:22 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/15/2026 08:08:03 PM
- PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access • Business Wire • 04/14/2026 04:00:00 PM
- Tempus AI Shares Gain After Expanded Partnership with Gilead • IH Market News • 04/10/2026 01:34:23 PM
- Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline • Business Wire • 04/07/2026 12:30:00 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 04/01/2026 08:34:18 PM
- Gilead Extends Tender Offer to Acquire Arcellx • Business Wire • 04/01/2026 08:13:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/30/2026 09:59:52 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/27/2026 08:03:17 PM
- Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases • Business Wire • 03/23/2026 10:15:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/20/2026 08:01:13 PM
- Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care • PR Newswire (Canada) • 03/19/2026 02:00:00 PM
- Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care • PR Newswire (US) • 03/19/2026 02:00:00 PM
